Company profile · Biotech & medical
Pell Bio-Med Technology
沛爾生技醫藥股份有限公司 · 6949
What it does
Drafted and translated from cited sources, with links to the passages they are based on for your verification. Care is taken to translate its original meaning from Mandarin as closely as possible.
Pell Bio-Med Technology develops genetically-modified immune cell products, non-genetically-modified cell therapy products, and non-cell products, focusing on cellular immunotherapy and genetic engineering of patients' own immune cells.[1]
The company develops chimeric antigen receptor T cell (CAR-T) therapy, and its products include cytokine-induced killer cells (CIK), dendritic cells co-cultured CIK cells (DC-CIK), adipose-derived mesenchymal stem cells (ADSC), and a hair tonic.[1]
Based in Taipei City, Taiwan, it is a biotechnology company engaged in cell culture technology research and development and clinical applications of cell therapy.[2]
Monthly revenue
| Latest month | Revenue | Year on year | Month on month |
|---|---|---|---|
| 2026-10 | NT$2m | +3.2% | +15.2% |
2024-11 to 2026-10, monthly revenue.
Foreign investors
| Last 20 trading days | Net |
|---|---|
| 2026-10-12 to 2026-11-10 | +NT$118m |
Net buying (green) and selling (red) by foreign investors, NT$ at each day's close. All companies.
Facts
| Full English name | PELL BIO-MED TECHNOLOGY CO., LTD. |
|---|---|
| Chinese name | 沛爾生技醫藥股份有限公司 |
| Stock code | 6949 (TWSE) |
| Industry | Biotech & medical |
| Founded | 30 Mar 2017 |
| Listed | 08 Mar 2024 |
| Paid-in capital | NT$656m |
| Chairman | 林成龍 |
| President | 林成龍 |
| Headquarters | 4F.,No.87,Xinhu 2nd Rd.,Neihu Dist., Taipei City ,Taiwan |
| Website | https://www.pellbmt.com |
| Official business description | 嵌合抗原受體T細胞(CAR-T)療法 · 特管辦法細胞產品 · 其他 |
Facts from MOPS company basic information, retrieved 03 Nov 2026. The official business description is the company's own entry and can be out of date.
Sources
- Annual report 2025 (English), business scope · annual_report · retrieved 04 Nov 2026
- MOPS 公司基本資料 沛爾生技醫藥股份有限公司 · mops · retrieved 04 Nov 2026
Using it at work? Join the team-plan waiting list